Fluocinolone Acetonide Implant as a Baseline Therapy for Diabetic Macular Edema: Results from the Randomized Phase 4 NEW DAY Study
Although the primary endpoint of rescue supplemental injection superiority was not met, FAc-treated participants achieved similar visual and anatomic improvements as those receiving aflibercept with fewer than half the number of total injections throughout the study. Safety data results were consistent with previous FAc implant studies.
Authors
- Michael Singer (ORCID: https://orcid.org/0000-0002-0149-4802)
- Christopher D. Riemann (ORCID: https://orcid.org/0000-0003-2022-0951)
- Mary Pao
- Scott Moody
- Christina Y. Weng
- Kamel Alkhatib
- Charles C. Wykoff
- Rohit A. Amarshi
- Victor H. Gonzalez
Institutions
- The University of Texas at San Antonio Health Science Center (US)
- Baylor College of Medicine (US)
- Medical Center Ophthalmology Associates (US)
- Retina Consultants of Texas (US)
- ANI Pharmaceuticals (United States) (US)
- Cincinnati Eye Institute (US)
- Valley Retina Institute (US)
Publication Details
- Journal
- Ophthalmology
- Published
- 2026-03-01
- DOI
- https://doi.org/10.1016/j.ophtha.2026.03.019
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00